STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,969 | -62.9% | 1,515 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $16,104 | +53.4% | 1,515 | +20.2% | 0.00% | 0.0% |
| Q1 2023 | $10,496 | -18.9% | 1,260 | -10.1% | 0.00% | 0.0% |
| Q4 2022 | $12,940 | -23.9% | 1,402 | +5.8% | 0.00% | 0.0% |
| Q3 2022 | $17,013 | -2.8% | 1,325 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $17,503 | -37.2% | 1,325 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $27,891 | -79.3% | 1,325 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $134,680 | -5.7% | 5,614 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $142,820 | -24.4% | 5,614 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $188,967 | +28.7% | 5,614 | +48.5% | 0.00% | +50.0% |
| Q1 2021 | $146,815 | -37.3% | 3,780 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $234,095 | +84.9% | 3,780 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $126,592 | -3.9% | 3,780 | -31.6% | 0.00% | 0.0% |
| Q2 2020 | $131,661 | +4.1% | 5,525 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $126,523 | +31.2% | 5,525 | +62.3% | 0.00% | +50.0% |
| Q4 2019 | $96,430 | – | 3,405 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |